Metabolism of Ursodeoxycholic Acid in Man

Fedorowski, Toni; Salen, Gerald; Colallilo, Anthony; Tint, G. Stephen; Mosbach, Erwin H.; Hall, James C.

doi:10.1016/s0016-5085(19)31871-2

Cited by 122 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 UDCA has relatively low aqueous solubility at intestinal pH 19,20 and at high doses would be poorly absorbed, making it difficult to achieve high serum UDCA enrichments, while increasing fecal LCA excretion. 28,29 Furthermore, because bile acid malabsorption is a feature of CF, it is difficult to achieve high biliary UDCA enrichments even with high doses of UDCA. 14 In previous CF studies, doses of 20 mg/kg/day of UDCA achieved a biliary enrichment of 42 AE 6%, somewhat lower than the 56 AE 0.2% enrichment reported for patients with PBC treated with a similar dose (18-21 mg/kg/day).…”

Section: Discussionmentioning

confidence: 99%

Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease

Colombo

Crosignani

Alicandro

et al. 2016

The Journal of Pediatrics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease

Colombo

Crosignani

Alicandro

et al. 2016

The Journal of Pediatrics

View full text Add to dashboard Cite

“…Liver conjugates these substances with glycine or with taurine. The presystemic metabolism is more complex: glyco-or tauro-derivatives are hydrolysed, bile acids formed can be dehydroxylated, whereas hydroxyl groups are easily epimerized, The deconjugated bile acid is newly absorbed through the intestine according to an enterohepatic circulation (12,13). .…”

Section: Bhe Acids As An Example Of Enterohepatic Circulationmentioning

confidence: 99%

Some pharmacokinetic considerations about homeostatic equilibrium of endogenous substances

Marzo

Rescigno

Martelli

1993

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

Endogenous substances in the body are controlled through simple, very effective mechanisms, that preserve an optimum homeostatic equilibrium of baseline concentration and restore it when impaired. When planning a pharmacokinetic investigation of an endogenous substance exogenously administered, it is imperative to carefully ascertain the above mechanisms as well as the baseline value and their possible variations associated with daily rhythm, food, age, sex, menstrual cycle. Often the control mechanisms operate through non-linear processes, therefore a non-compartmental analysis or a tailored model may be more appropriate than the compartmental models used in standard pharmacokinetic analysis. Some specific examples of endogenous substances are discussed here on the basis of the data from the literature and personal experience.

show abstract

“…Deoxych o lic acid and, more importantly, lithocholic acid virtually disap pear from the bile (80). In a comparative study of CDCA and UDCA fed to rhesus monkeys no liver toxicity was observed with UDCA (81).…”

Section: Ursodeoxycholic Acidmentioning

confidence: 99%

The Medical Treatment of Gallstones

Bouchier¹

1980

Annu. Rev. Med.

View full text Add to dashboard Cite

Metabolism of Ursodeoxycholic Acid in Man

Cited by 122 publications

References 17 publications

Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease

Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease

Some pharmacokinetic considerations about homeostatic equilibrium of endogenous substances

The Medical Treatment of Gallstones

Contact Info

Product

Resources

About